09:26 AM EDT, 10/07/2025 (MT Newswires) -- MannKind ( MNKD ) said Tuesday it has completed its acquisition of scPharmaceuticals (SCPH).

Under the terms of the deal, MannKind ( MNKD ) acquired all outstanding shares of scPharmaceuticals for $5.35 per share in cash and one contingent value right per share, which may pay up to $1 based on future milestones, according to the company.

The deal added Furoscix, a treatment for edema from chronic heart failure and kidney disease, to MannKind's ( MNKD ) portfolio and is expected to expand revenue growth in cardiometabolic care.

MannKind ( MNKD ) said it expects an annualized run rate above $370 million based on Q2 results.

Shares of MannKind ( MNKD ) were up 1% in recent Tuesday premarket activity.